Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Zolmitriptan is a highly selective serotonin 5-HT1B/1D receptor agonist belonging to the triptan class of medications, widely recognized as a first-line treatment for acute migraine attacks with or without aura. Its molecular formula is C13H17N3O2, and it carries the CAS registry number 146098-93-7. This compound functions by mimicking the action of endogenous serotonin, leading to the constriction of dilated intracranial blood vessels and the inhibition of the release of pro-inflammatory neuropeptides from trigeminal nerve endings. Unlike earlier non-specific vasoconstrictors, Zolmitriptan offers a targeted mechanism that effectively alleviates migraine symptoms such as severe headache, nausea, photophobia, and phonophobia without causing significant systemic vasoconstriction in peripheral arteries when used at therapeutic doses.
The drug is commercially available in various formulations, including immediate-release tablets, orally disintegrating tablets (ODT), nasal sprays, and injectable solutions, providing flexibility for patients who may experience nausea or vomiting during an attack. The ODT and nasal spray forms are particularly advantageous as they bypass the gastrointestinal tract, ensuring rapid absorption and quicker onset of pain relief. Clinical studies have consistently demonstrated its efficacy in achieving sustained pain freedom within two hours of administration, making it a preferred choice over placebo and other analgesics for moderate to severe migraines. While generally well-tolerated, common side effects include dizziness, paresthesia, dry mouth, and a sensation of warmth or tingling. It is contraindicated in patients with uncontrolled hypertension, ischemic heart disease, or those taking monoamine oxidase inhibitors due to the risk of serious cardiovascular events. As a generic medication, Zolmitriptan has become accessible globally, offering a cost-effective solution for millions suffering from debilitating migraines. Its development marked a significant advancement in neurology, shifting the paradigm from symptomatic relief to specific pathophysiological intervention in migraine management.